Andrea Sáez has been our Chief Development Officer since November 2023 and was previously our Head of Portfolio Development from January 2022 to November 2023. Prior to joining AgomAb she was Chief Operating Officer from July 2021 to January 2022 and Chief Scientific Officer from September 2020 to January 2022 at Origo Biopharma S.L., or Origo, which we acquired in 2021. Prior to joining Origo, Dr. Sáez was a Senior Associate and Associate, respectively, from June 2020 to September 2020 and October 2018 to June 2020 at Asabys Partners, a venture capital firm in Barcelona. From January 2015 to September 2018, Dr. Sáez was the Director of Research and Development at Pangaea Oncology and from May 2012 to January 2015, she was a Scientific and Regulatory Affairs Manager at Asphalion, a leading consultancy firm. Dr. Sáez was a Board Observer at ONA Therapeutics, a Barcelona-based biotechnology company, from May 2019 to June 2020. Dr. Sáez obtained a Ph.D. in Immunology at the Pompeu Fabra University followed by a postdoctoral stay at Vall d’Hebron Hospital where she studied and published on the therapeutic benefit of TGF-β inhibitors in preclinical cancer models.